Revenue declined 14% y-o-y to $3.18 million, mainly due to a lower revenue contribution from its medicinal cannabis manufacturing services provided to third parties.
iX Biopharma (SGX:42C
) has posted a lower loss attributable to shareholders of the company of $2.06 million for 1HFY2026 ended Dec 31, 2025, an improvement of 67% y-o-y from $6.25 million on back of favourable exchange rate.
Loss per share for 1HFY2026 was down to 0.23 cents, compared to 0.72 cents in 1HFY2025.
